Keros Therapeutics Inc (KROS) Stock Price, Quote & News

Company Profile

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in pat...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 314 6297

Website: www.kerostx.com

Address:

1050 Waltham Street, Suite 302, Lexington, United States

buyandsold Oct. 31 at 2:36 PM

$SPRO i have been screwed so many times by management, most recently the $KROS greenmail. What could they do to us here? It seems rock solid, but I guess they could decide to burn money starting new trials on something completely new. Other ways this seemingly safe and solid stock may blow up?

2 · Reply

Anywhere_but_backwards Oct. 27 at 6:59 PM

$LUMN to the moon. Same as $ALAB, $MBLY, $KROS

0 · Reply

CyberCuba Oct. 24 at 8:50 PM

$KROS Options have been very very active. Seems the algorithms buy a call option for protection then short the stock or buy call put options (straddles) until the tender offer is finalized.

1 · Reply

CyberCuba Oct. 23 at 10:33 PM

$KROS With yesterday's SEC filing it appears Tang Capital partners in San Diego has increased its ownership of KROS shares from 1.4 million per Yahoo to 2.4 million per yesterday's SEC filing or a little over 7% of the 30 million KROS shares now outstanding. If the preceding numbers are correct, it seems unlikely Tang would turn around and try to unload some shares at the tender offer of $17.75. If KROS is above $20 per share next Spring after the upcoming tender offer closes, this tender offer will look like a very smart corporate move.

0 · Reply

okiejames Oct. 23 at 3:53 PM

$KROS so now they're trying to buyback shares from retail for the 17.75

0 · Reply

okiejames Oct. 20 at 7:26 PM

$KROS that volume

0 · Reply

CyberCuba Oct. 20 at 7:09 PM

$KROS Good third quarter earnings (or less loss) or positive conference call may put KROS over $18 when reported in early November (25 cents above tender offer price of $17.75)

0 · Reply

Thestocktraderhubzee Oct. 20 at 10:05 AM

$KROS Keros Therapeutics Announced That It Has Commenced A Cash Tender Offer To Repurchase Up To $194.4M Of Shares Of The Company's Common Stock At A Purchase Price Of $17.75 Per Share

1 · Reply

CyberCuba Oct. 19 at 2:08 PM

$KROS KROS sold 4,025,000 shares at $40 per share to the public January 9, 2024. Now 22 months later, KROS will make a tender offer at $17.75 for over 10,000,000 shares. Pretty savvy move to buy back shares at a 45% discount to the $40 offering in 2024.

3 · Reply

buyandsold Oct. 17 at 11:30 PM

$KROS the Takeda asset is well hidden under a management intend on burning cash to pay their mortgages

0 · Reply

Keros Therapeutics Commences Issuer Tender Offer to Repurchase up to $194.4 Million Shares

Oct 15, 2025, 6:30 AM EDT - 16 days ago

Keros Therapeutics Announces Plan for Return of $375 Million in Excess Capital

Sep 8, 2025, 8:00 AM EDT - 7 weeks ago

Keros Therapeutics Presents Additional Clinical Data from its KER-065 Program at the American Society of Bone and Mineral Research 2025 Annual Meeting

Aug 28, 2025, 4:01 PM EDT - 2 months ago

Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences

Aug 21, 2025, 8:30 AM EDT - 2 months ago

ADAR1 Sends Open Letter to Keros Board of Directors Urging the Board to Engage Constructively on Strategy, Capital Allocation and Board Refreshment

Aug 20, 2025, 9:48 AM EDT - 2 months ago

Keros Announces U.S. FDA Orphan Drug Designation Granted to KER-065 for the Treatment of Duchenne Muscular Dystrophy

Aug 6, 2025, 4:15 PM EDT - 3 months ago

Keros to Exclusively Prioritize the Clinical Advancement of KER-065

Aug 6, 2025, 4:01 PM EDT - 3 months ago

Keros Therapeutics Reports Second Quarter 2025 Financial Results

Jul 17, 2025, 8:00 AM EDT - 3 months ago

Keros Therapeutics Announces the First Patient Dosing in the Phase 3 RENEW Clinical Trial of Elritercept

Jun 9, 2025, 3:12 PM EDT - 5 months ago

ADAR1 Issues Statement on Keros Therapeutics' Troubling 2025 Director Election Results and Insufficient Capital Return Proposal

Jun 9, 2025, 6:55 AM EDT - 5 months ago

Keros Announces Return of $375 Million in Excess Capital to Stockholders

Jun 6, 2025, 4:01 PM EDT - 5 months ago

Keros Therapeutics Announces Participation at Goldman Sachs 46th Annual Global Healthcare Conference

May 29, 2025, 6:55 AM EDT - 5 months ago

Keros Therapeutics Announces TROPOS Topline Data and Corporate Restructuring

May 27, 2025, 1:45 PM EDT - 5 months ago

Leading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote “FOR” All of Keros' Director Nominees

May 21, 2025, 8:00 AM EDT - 5 months ago

ADAR1 Announces ISS Recommends Keros Therapeutics Stockholders WITHHOLD Votes from Directors Dr. Mary Ann Gray and Dr. Alpna Seth

May 12, 2025, 12:11 PM EDT - 6 months ago

ADAR1 Capital Management Releases Investor Presentation Outlining Its Rationale for Withholding Votes From Directors Dr. Mary Ann Gray and Dr. Alpna Seth

May 12, 2025, 8:00 AM EDT - 6 months ago

Keros Therapeutics Announces Participation at Bank of America 2025 Global Healthcare Conference

May 8, 2025, 5:31 PM EDT - 6 months ago

Keros Reinforces Commitment to Maximizing Stockholder Value

May 8, 2025, 2:10 PM EDT - 6 months ago

ADAR1 Capital Management Issues Open Letter to Keros Therapeutics Stockholders

May 6, 2025, 4:01 PM EDT - 6 months ago

Keros Therapeutics Reports Recent First Quarter 2025 Financial Results

Apr 10, 2025, 1:51 PM EDT - 7 months ago

Keros Therapeutics Goes Up For Sale On Heels Of Stockholder Rights Plan

Apr 10, 2025, 12:12 PM EDT - 7 months ago

Crude Oil Falls Over 4%; Keros Therapeutics Shares Jump

Apr 10, 2025, 6:10 AM EDT - 7 months ago

Keros Therapeutics adopts 'poison pill' plan

Apr 10, 2025, 6:00 AM EDT - 7 months ago

Keros Therapeutics Announces Review of Strategic Alternatives

Mar 31, 2025, 6:00 AM EDT - 7 months ago

Keros Therapeutics Announces Initial Topline Results from the Phase 1 Clinical Trial of KER-065 in Healthy Volunteers

Feb 26, 2025, 4:01 PM EST - 8 months ago

Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

Feb 19, 2025, 10:41 AM EST - 9 months ago

Fat, not muscle: Drugmakers in race for next weight-loss breakthrough

ARWR AZN BHVN LLY NVO REGN SRRK

Jan 31, 2025, 10:00 AM EST - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Keros Therapeutics, Inc. (KROS) and Encourages Shareholders to Learn More About the Investigation

Jan 30, 2025, 10:00 AM EST - 9 months ago

Keros Therapeutics, Inc. (KROS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Jan 30, 2025, 8:00 AM EST - 9 months ago

Keros Therapeutics to Present at the Guggenheim SMID Cap Biotech Conference

Jan 29, 2025, 10:00 AM EST - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Keros Therapeutics, Inc. (KROS) Shareholders to Inquire about Securities Investigation

Jan 28, 2025, 10:00 AM EST - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Keros Therapeutics, Inc. (KROS) And Encourages Shareholders to Connect

Jan 27, 2025, 10:00 AM EST - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Keros Therapeutics, Inc. (KROS) Stockholders to Inquire about Securities Investigation

Jan 26, 2025, 10:00 AM EST - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Keros Therapeutics, Inc. (KROS) and Encourages Investors to Learn More About the Investigation

Jan 24, 2025, 10:00 AM EST - 10 months ago

Keros Therapeutics, Inc. (KROS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Jan 23, 2025, 10:00 AM EST - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Keros Therapeutics, Inc. (KROS) And Encourages Investors to Connect

buyandsold Oct. 31 at 2:36 PM

2 · Reply

Anywhere_but_backwards Oct. 27 at 6:59 PM

$LUMN to the moon. Same as $ALAB, $MBLY, $KROS

0 · Reply

CyberCuba Oct. 24 at 8:50 PM

$KROS Options have been very very active. Seems the algorithms buy a call option for protection then short the stock or buy call put options (straddles) until the tender offer is finalized.

1 · Reply

CyberCuba Oct. 23 at 10:33 PM

0 · Reply

okiejames Oct. 23 at 3:53 PM

$KROS so now they're trying to buyback shares from retail for the 17.75

0 · Reply

okiejames Oct. 20 at 7:26 PM

$KROS that volume

0 · Reply

CyberCuba Oct. 20 at 7:09 PM

$KROS Good third quarter earnings (or less loss) or positive conference call may put KROS over $18 when reported in early November (25 cents above tender offer price of $17.75)

0 · Reply

Thestocktraderhubzee Oct. 20 at 10:05 AM

$KROS Keros Therapeutics Announced That It Has Commenced A Cash Tender Offer To Repurchase Up To $194.4M Of Shares Of The Company's Common Stock At A Purchase Price Of $17.75 Per Share

1 · Reply

CyberCuba Oct. 19 at 2:08 PM

3 · Reply

buyandsold Oct. 17 at 11:30 PM

$KROS the Takeda asset is well hidden under a management intend on burning cash to pay their mortgages

0 · Reply

CyberCuba Oct. 17 at 12:53 AM

$KROS What if? KROS likely knows what its earnings will be when it reports third quarter earnings in November. Outstanding shares may be as low as 20 million if the full tender offer is successful. A positive earnings surprise with greatly reduced outstanding shares may catapult the share price above the tender offer of $17.75.

1 · Reply

G101SPM Oct. 16 at 3:17 PM

#INSIDERS $RGP President & Chief Executive Officer bought 23,015 shares at $4.X.335 - $4.X.37 worth approximately $100K. $CRWV 10% owner Magnetar sold 415,113 shares of Class A Common Stock worth approximately $58.6 mln. $KROS 10% owner sold 5,389,264 shares worth nearly $95.7 mln. $VOR 10% owner Reprogrammed Interchange sold 96,657 shares at $30.00 - $33.14 worth more than $3 mln.

0 · Reply

okiejames Oct. 16 at 10:57 AM

$KROS what bs was that yesterday. Totally didnt go the way i figured

0 · Reply

Bullish_Trader555 Oct. 15 at 9:28 PM

$KROS

0 · Reply

CyberCuba Oct. 15 at 7:32 PM

$KROS Buying out "complete holdings of disgruntled large shareholders to simply go away" at a premium to their cost basis used to be called "greenmail".

1 · Reply

okiejames Oct. 15 at 1:48 PM

$KROS well i guess im going to avg up

1 · Reply

Bullish_Trader555 Oct. 15 at 1:42 PM

$KROS $LLY $SPY

0 · Reply

CyberCuba Oct. 15 at 1:16 PM

$KROS with all the repurchases, if successful by the company's tender offer, the number of outstanding shares will be 20 million instead of 40 million. EPS should go up accordingly.

1 · Reply

okiejames Oct. 15 at 12:38 PM

$KROS so the money that was supposed to be returned to shareholders wont happen till 2028? Did i read that right?

0 · Reply

OpenOutcrier Oct. 15 at 12:21 PM

$KROS (+1.2% pre) Keros jumps on plan to return $375M in excess capital https://ooc.bz/l/80522

0 · Reply

Bullish_Trader555 Oct. 15 at 11:10 AM

$KROS Announces Plan for Return of $375M in Excess Capital via Tender Offer to Repurchase up to $194M of Additional Shares at $17.75/shr - $LLY $SPY

1 · Reply

CyberCuba Oct. 14 at 6:24 PM

$KROS Time for ADAR in Austin to nominate a slate of new directors.

1 · Reply

Market Cap	458.21M
Revenue (ttm)	3.55M
Net Income (ttm)	-187.35M
EPS (ttm)	N/A
PE Ratio	48.48
Forward PE	45.72
Profit Margin	-5,277.47%
Debt to Equity Ratio	0.00

Volume	666,200
Avg Vol	690,092
Day's Range	N/A - N/A
Shares Out	30.47M
Stochastic %K	60%
Beta	0.97
Analysts	Sell
Price Target	$23.00